Factor VII for excessive bleeding following congenital heart disease surgery.

Recombinant activated factor VII may be effective in patients with severe bleeding following congenital heart disease surgery requiring cardiopulmonary bypass. From August 2009 through June 2011, 13 patients (median age, 5 months) were given recombinant activated factor VII for severe bleeding after open heart surgery, preventing sternal closure 2 h after completion of cardiopulmonary bypass, or chest tube drainage >10 mL · kg(-1) · h(-1) for 2 h. The median dose was 75 μg · kg(-1).